Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10540891 | 0.85 | GFER (0.42) | GFERMAOBMAOAALDH1A1CA12 | |
| SCHEMBL8866936 | 0.84 | GFER (0.62) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL8164156 | 0.82 | GFER (1.00) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL187043 | 0.82 | GFER (1.00) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL3482833 | 0.82 | GFER (1.00) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL8866768 | 0.80 | RAB9A (0.68) | GFERTDP1MEN1MAPTKMT2A | |
| SCHEMBL14048182 | 0.80 | GFER (0.72) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL8653872 | 0.79 | GFER (0.93) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL8867927 | 0.78 | HRH3 (0.52) | LOXL2MAPTCA12CA1CA2 | |
| SCHEMBL12110702 | 0.77 | GFER (0.77) | GFERMAOBMAOAALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5955601-A | USEFUL IN NUCLEIC ACID HYBRIDIZATION ASSAYS AND FOR GENERATING LABELLED PROBES; UNUSUALLY HIGH EFFICIENCY OF RARE EARTH ELEMENT CAPTURE CORRELATED WITH EMISSION OF A HIGH LEVEL OF SIGNAL IN TIME-RESOLVED FLUORESCENCE SPECTROSCOPY | E G & G WALLAC (FI) | 1999-09-21 | — | — | US | claimed |
| EP-0525181-B1 | NOVEL LANTHANIDE CHELATE-CONJUGATED OLIGONUCLEOTIDES | DADE MICROSCAN INC (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0525181-A4 | NOVEL LANTHANIDE CHELATE-CONJUGATED OLIGONUCLEOTIDES | — | 1993-03-10 | — | — | EP | claimed |
| EP-0525181-A1 | NOVEL LANTHANIDE CHELATE-CONJUGATED OLIGONUCLEOTIDES. | BAXTER DIAGNOSTICS INC (US) | 1993-02-03 | — | — | EP | claimed |
| WO-1992014841-A1 | NOVEL LANTHANIDE CHELATE-CONJUGATED OLIGONUCLEOTIDES | BAXTER DIAGNOSTICS INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-2338886-A2 | Naphthalene derivatives | Novartis AG (CH) | 2011-06-29 | — | — | EP | disclosed |
| US-7045533-B2 | Such as naphthalen-1-yl-(4-pentyloxy-naphthalen-1-yl)-mehtane for treatment/prevention of diseases/conditions associated with cannobinoid receptor activation such as chronic pain, osteo- and rheumatoid arthritis, teno-synovitis and gout | NOVARTIS AG (CH) | 2006-05-16 | — | — | US | disclosed |
| WO-2005058292-A1 | NEW USE IN GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | WO | disclosed |
| US-20040053890-A1 | Naphthalene derivatives | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1339663-A2 | NAPHTHALENE DERIVATIVES | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042248-A2 | NAPHTHALENE DERIVATIVES | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
| US-5955601-A | USEFUL IN NUCLEIC ACID HYBRIDIZATION ASSAYS AND FOR GENERATING LABELLED PROBES; UNUSUALLY HIGH EFFICIENCY OF RARE EARTH ELEMENT CAPTURE CORRELATED WITH EMISSION OF A HIGH LEVEL OF SIGNAL IN TIME-RESOLVED FLUORESCENCE SPECTROSCOPY | E G & G WALLAC (FI) | 1999-09-21 | — | — | US | disclosed |
| EP-0232623-B1 | 1-CARBACEPHALOSPORIN ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1993-03-17 | — | — | EP | disclosed |
| EP-0525181-A4 | NOVEL LANTHANIDE CHELATE-CONJUGATED OLIGONUCLEOTIDES | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0525181-A1 | NOVEL LANTHANIDE CHELATE-CONJUGATED OLIGONUCLEOTIDES. | BAXTER DIAGNOSTICS INC (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1992014841-A1 | NOVEL LANTHANIDE CHELATE-CONJUGATED OLIGONUCLEOTIDES | BAXTER DIAGNOSTICS INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| US-4892942-A | 1-CARBA (DETHIA)CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1990-01-09 | — | — | US | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4332809-A | ANTIALLERGENS | TANABE SEIYAKU CO., LTD. (JP) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053890-A1 | Naphthalene derivatives | CYP1A1, SULT1E1, CYP2F1 | GFER 3130/4885MAOB 856/4885MAOA 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.